Liquid vs. pill: new study tests easier way to take seizure drug

NCT ID NCT07176832

Completed Knowledge-focused Sponsor: Biocodex Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two versions of the seizure medication stiripentol (Diacomit®) in 24 healthy adults: a capsule and a liquid suspension. The goal was to see if the liquid form is absorbed by the body in a similar way to the capsule. If so, it could provide a more convenient option for children and adults with Dravet syndrome who have difficulty swallowing pills. The study also checked for side effects and how the liquid tastes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stiripentol (Diacomit®)
What this could lead to: If the oral suspension works as well as the capsule, it could offer a more convenient liquid option for people with Dravet syndrome who have trouble swallowing pills.
What could go wrong: This is a small, early-stage study in healthy volunteers, not patients. It only looks at how the drug is absorbed, not whether it actually helps control seizures. The liquid form may not prove equally effective in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood-onset epilepsy syndrome developmental and epileptic encephalopathy Dravet syndrome Epilepsies, Myoclonic epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD DRAVET SYNDROME EPILEPSY EPILEPTIC ENCEPHALOPATHY PEDIATRIC EPILEPSY

Contacts and locations

Locations

3 Chemin d'Armancourt

Compiègne, 60200, France
EUROFINS OPTIMED, 1 rue des Essarts

Gières, 38610, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.